We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Measurable residual disease in multiple myeloma: ready for clinical practice?
- Authors
Burgos, Leire; Puig, Noemi; Cedena, Maria-Teresa; Mateos, María-Victoria; Lahuerta, Juan José; Paiva, Bruno; San-Miguel, Jesús F.
- Abstract
The landscape of multiple myeloma (MM) has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess measurable residual disease (MRD) as the most accurate method to evaluate treatment efficacy. The sensitivity and standardization achieved by these techniques together with unprecedented rates of complete remission (CR) induced by new regimens, raised enormous interest in MRD as a surrogate biomarker of patients' outcome and endpoint in clinical trials. By contrast, there is reluctance and general lack of consensus on how to use MRD outside clinical trials. Here, we discuss critical aspects related with the implementation of MRD in clinical practice.
- Subjects
MULTIPLE myeloma; TREATMENT effectiveness; CLINICAL trials; DISEASES; BIOLOGY
- Publication
Journal of Hematology & Oncology, 2020, Vol 13, Issue 1, p1
- ISSN
1756-8722
- Publication type
Article
- DOI
10.1186/s13045-020-00911-4